Comparison · NCT00002874-3f2a32b4
Bicalutamide vs Placebo: PSA Complete Response at End of Protocol Treatment
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Bicalutamide vs Placebo: PSA Complete Response at End of Protocol Treatment. Trial comparisons, record NCT00002874-3f2a32b4. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00002874-3f2a32b4
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.938 | 0.909 | 0.958 | wilson | |
| Risk in group 2 | 0.689 | 0.64 | 0.734 | wilson | |
| Risk difference, group 1 minus group 2 | 0.249 | 0.195 | 0.301 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.36 | 1.27 | 1.46 | log | |
| Odds ratio, group 1 over group 2 | 6.78 | 4.25 | 10.8 | log | |
| Number needed to treat, for one more participant with the outcome on Bicalutamide than on Placebo | 4.02 | 3.32 | 5.12 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Bicalutamide | Radiation therapy (64.8 Gy) + bicalutamide (150 mg daily 2 years) | 360 | 384 | OG001 |
| Group 2 | Placebo | Radiation therapy (64.8 Gy) + placebo (daily 2 years) | 259 | 376 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- PSA Complete Response at End of Protocol Treatment
- Description
- Complete response is defined as a drop in PSA on protocol treatment to less than 0.2 ng/ml. Note that when the study opened many institutions could not detect PSA \< 05 ng/ml.
- Time frame
- End of protocol treatment, which is planned to last for two years
- Population
- Eligible patients who did not withdraw consent.
Source ClinicalTrials.gov
Trial
- Title
- Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy
- NCT number
- NCT00002874
- Phases
- PHASE3
- Conditions
- Prostate Cancer
- Interventions
- bicalutamide, radiation therapy, placebo
- Lead sponsor
- Radiation Therapy Oncology Group
- Results first posted
- 2017-08-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00002874?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00002874-3f2a32b4